Proactive Investors - Run By Investors For Investors

Faron Pharma finance boss to transition into new role next month

Yrjö Wichmann is stepping down as CFO to become Faron’s new Vice President, Financing and Investor Relations, and he will be replaced by Toni Hänninen
board room
Hänninen is joining from Fortune 500 group Danaher

Drug developer Faron Pharmaceuticals Ltd’s (LON:FARN) has unveiled plans to reshuffle its boardroom ahead of next week's annual general meeting in Finland.

Chief financial officer Yrjö Wichmann is to step down from his current position to take up the new role of Vice President, Financing and Investor Relations.

READ: Faron raises €1.34mln from existing shareholder

Faron said this will allow him to focus on the company’s “future financing and investor relationships”.

Wichmann will remain a member of the senior management team but will step down from the board next month (June).

Replacing him as CFO will be Toni Hänninen, who will join from Fortune 500 science and technology group Danaher on 1 June.

Hänninen will bring “extensive global experience” which the company said will be “very relevant” as it looks to progress its product portfolio and international commercial development.

‘Changes will strengthen the company’

“These managerial changes will strengthen our operations by allowing Yrjö to focus on the company's future financing,” said chief executive Markku Jalkanen.

“We also believe this will increase Faron's capacity to attract external financing and enable us to better maintain and develop investor relationships and target an expanded future shareholder base.

“I am delighted that Toni has decided to join Faron. His vast experience, from international director and controller positions, will help us to advance our international accounting processes and internal reporting.”

Faron shares were down 0.5% to 103.5p.

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

Related Articles

word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use